天天舔天天爽_视频日韩_成人网线_天天草草草_免费一级在线观看_色综合色综合色综合色综合

海正藥業 HISUN Pharmaceuticals   
 始創于1956年的浙江海正藥業股份有限公司（股票代碼600267，以下簡稱“海正藥業”）秉承“執著藥物創新，成就健康夢想”的使命和“成為廣受尊重的全球化制藥企業”的愿景，致力于整合藥物研發與生產資源，為全球客戶提供更好的產品和服務，通過美國FDA、歐盟EDQM、澳大利亞TGA、韓國KFDA等官方認證的品種達到40多個，銷往全球30多個國家和地區。
2009年，公司榮獲“全國五一勞動獎狀”，海正、HISUN及圖形被認定為“中國馳名商標”，入選“中國萬種微生物基因組計劃”和“國家重大（磅）級藥物品種產業化技術創新聯盟”。因圓滿完成“抗甲流藥物中間體生產”的國家任務，受到省政府的通令嘉獎。
2010年，公司入選浙江省醫藥工業“十強企業”，并榮獲“國內最佳產品線十佳工業企業” 稱號，同時被譽為“金蜜蜂獎成長型企業”。



Founded in 1956, the mission for Zhejiang HISUN Pharmaceuticals Co., Ltd. (stock code 600267) hereinafter called "HISUN") is one of "To be persistent in pharmaceutical innovation for humans' well-being". The company's vision is to become "a widely respected global pharmaceutical provider".It focuses on the integration of pharmaceutical research and development (R&D) with production resources in order to provide its global customers with outstanding products and services.To date, over 40 of the company's products have passed certification by the FDA (U.S.),EDQM (EU) ,TGA (Australia) ,KFDA(Korea), etc.,and are sold to more than 30 countries worldwide.

Over the years, HISUN has received numerous commendations and accolades. For example, in 2009 the company received the "May 1st Labor Award". The company's name in Chinese and English (HISUN) and its logo were recognized as "Famous Brands in China". The company was also selected to participate in "China's Genome Project for 10,000 Micro-organisms" and "National Technical Innovation Alliance for Commercialization of Major Pharmaceuticals". As a result of its successful completion of the Central Government's assignment with respect to the production of "anti-H1N1 pharmaceutical intermediate agents", the company was commended by the Zhejiang Provincial Government.

In 2010, Hisun was selected as the "Top 10 Enterprises " of ZheJiang Medicine Industry, and honored as the "Top 10 Industrial Enterprises of Optimum Product Lines in China ", and at the same time, Hisun awarded the "Gold Bee Prize of Growing Enterprise". At the same year, Hisun achived sales revenue of RMB 4.5 billion, total profit of RMB 450 million, which were 14.4% and 28.2% respectively higher than the previous year.